BJH - volume 13, issue 1, february 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
During the 63rd annual meeting of ASH, again hundreds of interesting oral abstracts and poster presentations in the field of aggressive and indolent lymphoma were discussed. In this article, we will highlight some of the most promising data in the field of diffuse large B-cell lymphoma, classic Hodgkin lymphoma, enteropathy-associated T-cell lymphoma, mantle cell lymphoma and follicular lymphoma.
(BELG J HEMATOL 2022;13(1):29-36)
Read moreBJH - volume 13, issue 1, february 2022
B. Heyrman MD
The first hybrid ASH meeting lived up to the expectation of bringing new data forward that will change the life of MDS patients. Implementation of NGS in daily practice has unveiled intimate information of the disease and is moving forward into risk scores. A new and better standard risk score will change our treatment approach thereby changing the outcome of our patients. For now, we are watching new molecules grow through different trial phases and becoming impatient to install them into daily practice in the near future. A summary of the most appealing data in the field of MDS is presented here.
(BELG J HEMATOL 2022;13(1):25-8)
Read moreBJH - volume 13, issue 1, february 2022
D. Mazure MD
As every year, ASH 2021 brought us updates on current practice, new insights and promising future treatments. I have tried to select the most relevant data from the educational sessions and oral and poster abstracts that can influence our current and near-future practice in chronic myeloid leukaemia (CML) and myeloproliferative neoplasm (MPN).
(BELG J HEMATOL 2022;13(1):17–24)
Read moreBJH - volume 13, issue 1, february 2022
T. Feys MBA, MSc
The research landscape in chronic lymphocytic leukaemia (CLL) anno 2022 puts a strong focus on the optimal treatment choice in the frontline setting. In this setting, targeted therapy options have largely replaced chemoimmunotherapy as standard of care. However, with this evolution comes a new question: which patient is best treated with a continuous treatment option and who benefits most from a time-limited treatment approach? During ASH 2021, results of several studies looking at both treatment strategies have been presented, further fuelling this debate. Despite the impressive improvements in the frontline setting, a large proportion of patients will eventually relapse or develop refractoriness to the available therapies. To address this medical need, researchers continue to develop new treatment modalities. In this light, ASH 2021 featured promising results with the novel BTK-inhibitor pirtobrutinib and provided a reassuring update of the ASCEN trial evaluating acalabrutinib in the relapsed/refractory setting.
(BELG J HEMATOL 2022;13(1):11–6)
Read more
Top
